AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation

TAIPEI, June 22, 2026 /PRNewswire/ — AnHorn Medicines today announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuropathy (CIPN), has achieved two major regulatory milestones: Investigational New Drug (IND) clearance from…

Read the full release →

News provided by PR Newswire.